Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00978302
Other study ID # RN1001-319-1001
Secondary ID
Status Completed
Phase Phase 1
First received September 15, 2009
Last updated September 15, 2009
Start date May 2001
Est. completion date August 2001

Study information

Verified date September 2009
Source Renovo
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and local toleration and histological effects of various dose levels of avotermin (Juvista) injected intradermally in healthy male volunteers.


Description:

The study was split into two Cohorts: A and B. Volunteers in Cohort A were assigned to one of four dose groups receiving 50, 100, 500 and 1000ng/100μl/3mm punch biopsy. Volunteers were assigned sequentially in order of ascending dose. Within each dose group volunteers were further randomised to subgroup a, b or c. Each subject was set to receive four 3mm punch biopsies, two on each arm, and intradermal injection of avotermin, placebo or nothing (standard care).

On day 0 two 3mm punch biopsies were administered under local anaesthesia to the inner aspect of one arm of each subject following intradermal injection of avotermin, placebo or nothing. The four subjects in subgroup a received avotermin to one punch biopsy and placebo to the other. The four subjects in subgroup b received avotermin to one punch biopsy and standard care only to the other. The one subject in subgroup c was administered with intradermal placebo to one biopsy and standard care only to the other. 24 h later a further application of intradermal avotermin, placebo or nothing was applied.

While arm 1 was used as a study arm, arm 2 was used for safety procedures. Subjects were then randomised to return on Day 3 or 7 for excision of the first two punch biopsies. At the same time two punch biopsies and the same treatment regime was carried out on the second arm. These were dosed again 24 h later and all were excised on Day 10.

After determining safety and toleration of all doses in Cohort A, new subjects were assigned to Cohort B. These were allocated in ascending order to groups that would receive 1, 10, 50 and 100μg/100μl/3mm punch biopsy, following the same procedures that were used for Cohort A. Only after the first three groups reached Day 10 and the safety data was analysed would the final volunteers be recruited to the 100μg group.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date August 2001
Est. primary completion date August 2001
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Healthy, caucasian male subjects

- Weight between 60 and 150 kg and a BMI within the permitted range for their height using Quetelet's index (weight (kg)/height (m) squared. The permitted index is between 15-45 kg/m squared

- Subjects who have a previous history of surgery or minor injury and who have not developed any evidence of hypertrophic or keloid scar formation

Exclusion Criteria:

- Subjects with evidence of hypertrophic or keloid scarring

- Subjects with tattoos or previous scars in the biopsy areas

- Subjects with evidence of any past or present clinically significant disease, particularly coagulation disorders, immuno-mediated conditions and skin diseases and allergies such as eczema

- Subjects with a history of clinically significant allergies, especially drug hypersensitivity to lignocaine or allergy to the surgical dressings to be used in this study

- Subjects with any clinically significant abnormality following review of pre-study laboratory data and full physical examination

- Subjects who are taking or have taken any prescribed drug in the three weeks prior to day 0 and in particular topical or systemic steroids, anti-inflammatory and anti-coagulant drugs

- Subjects who drink more than 28 units of alcohol per week

- Subjects who have evidence of drug abuse

- Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B surface antigen.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Avotermin
Intradermal injection, 50ng/100µl/3mm punch biopsy, once at time of biopsy and again 24 h later
Avotermin
Intradermal injection, 100ng/100µl/3mm punch biopsy, once at time of biopsy and again 24 h later
Avotermin
Intradermal injection, 500ng/100µl/3mm punch biopsy, once at time of biopsy and again 24 h later
Avotermin
Intradermal injection, 1000ng/100µl/3mm punch biopsy, once at time of biopsy and again 24 h later
Avotermin
Intradermal injection, 1µg/100µl/3mm punch biopsy, once at time of biopsy and again 24 h later
Avotermin
Intradermal injection, 10µg/100µl/3mm punch biopsy, once at time of biopsy and again 24 h later
Placebo (vehicle)
Intradermal injection at time of biopsy and again 24 h later

Locations

Country Name City State
United Kingdom Renovo Clinical Trials Unit Manchester

Sponsors (1)

Lead Sponsor Collaborator
Renovo

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the safety and local toleration of various dose levels of avotermin (Juvista) injected intradermally into healthy male volunteers. Days 0 and 1 and either 3 and 4 or 7 and 8 in addition to Day 10. A single post-trial follow-up was made between days 17-24. Yes
Secondary To determine the systemic PK of various dose levels of avotermin (Juvista) injected intradermally. Days 0 and 1 and either 3 and 4 or 7 and 8, in addition to day 10. A single post-trial follow-up was made between days 17-24. Yes
Secondary To determine the histological effects (re-epithelialisation and wound healing) of avotermin (Juvista) injected intradermally. Days 3, 7 and 10. No
See also
  Status Clinical Trial Phase
Completed NCT05045183 - A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated N/A
Enrolling by invitation NCT04613336 - Efficacy of Topical Heparin Spray on Donor Site Wound Healing Time Compared to Conventional Dressing Among Patients Undergoing Split Thickness Skin Grafting
Recruiting NCT02241811 - Wound Treatment With 3% Sodium Pentaborate Pentahydrate Phase 1
Completed NCT02797899 - Effect of PRF Palatal Bandage on Pain Scores and Wound Healing After Free Gingival Graft N/A
Completed NCT01227759 - Tyrosur® Gel-Investigation on Wound Healing Efficacy Phase 2
Completed NCT01061502 - Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds Phase 1/Phase 2
Completed NCT00736593 - A Study Evaluating Nexagon™ in the Treatment of Skin Wounds. Phase 1
Completed NCT00977951 - Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects Phase 1/Phase 2
Not yet recruiting NCT03872544 - Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Enrolling by invitation NCT03880188 - Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Recruiting NCT05191082 - Manufacturing, Characterization and Evaluation of the Effect of Silk Fibroin Membranes, Loaded or Not With Neurotensins on Open Wounds in the Palate N/A
Enrolling by invitation NCT05942235 - The Use of Microlearning in Nursing Education
Completed NCT03433820 - Wound Healing in Healthy Volunteers N/A
Withdrawn NCT02383992 - Postoperative Care of Sutured Wounds N/A
Recruiting NCT02034539 - VADOplex Critical Limb Ischemia Study Phase 2/Phase 3
Recruiting NCT01680042 - Clinical Effect of Phenytoin Mucoadhesive Paste on Wound Healing After Oral Biopsy Phase 1
Completed NCT01734317 - An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver. N/A
Completed NCT01115218 - The Influence of Anterior Chamber Fluid Mediators on the Success Rate of Trabeculectomy
Withdrawn NCT01008111 - Wound Healing of Incisional Wounds for Bilateral Hernia Repair Phase 1
Terminated NCT00177060 - Topical Hydromorphone for Wound Healing Phase 1/Phase 2